Phico Saspject News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: May 12, 2021 By Alex Keown Shanghai continues to be an area of focus for many pharmaceutical companies seeking a toehold in China. Companies like AstraZeneca, Novartis and others have opened offices in Shanghai. Two months ago, Germany’s Vetter, a contract development and manufacturing organization, opened offices there, and now, ITM AG, another Germany-based company is following suit. ITM AG established a subsidiary in Shanghai to accelerate introduction of its precision oncology portfolio in China. The subsidiary will expand ITM’s growing operations in China, which is...

Phico Therapeutics gains £13.1m grant to advance antibacterial therapy 19th April 2021 Cambridge, UK-based Phico Therapeutics has been awarded a grant of up to £13.2m ($18.2m) to take its lead antibacterial therapy through Phase I clinical trials. The grant comes from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership seeking to accelerate antibacterial research against the growing threat of drug-resistant bacteria. The funds will be used to support the advancement of Phico’s lead product – SASPject PT3.9 – through clinical...